


12-30-02

1646

Express Mail Label No.: EV-38525805US

Date of Deposit: December 27, 2002

Attorney Docket No. 22058-516-DIV-CON
GI 9292A-D2-C1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: James Tobin

SERIAL NUMBER: 09/924,338

FILING DATE: August 7, 2001 ART UNIT: 1646

FOR: METHOD COMPRISING THE USE OF HUMAN INTERLEUKIN-11
RECEPTOR PROTEINS

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

JAN 02 2003

TRANSMITTAL LETTER

TECH CENTER 1600/2900

Transmitted herewith for filing in the present application are the following documents:

1. Response to Office Action Dated November 29, 2002 and Supplemental Preliminary Amendment (6 pages), and,
2. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 22058-516 DIV CON. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifji, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241



30623

PATENT TRADEMARK OFFICE


Dated: December 27, 2002

TRA 1747708v1

Express Mail Label No.: EV138525805US

Date of Deposit: December 27, 2002

Attorney Docket No. 22058-516-DIV-CON
GI 9292A-D2-C1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: James Tobin

SERIAL NUMBER: 09/924,338

FILING DATE: August 7, 2001 ART UNIT: 1646

FOR: METHOD COMPRISING THE USE OF HUMAN INTERLEUKIN-11
RECEPTOR PROTEINS

TECH CENTER 1600/2930

RECEIVED
JAN 02 2003

Response to Office Action Dated November 29, 2002 and Supplemental Preliminary
Amendment

In response to the November 29, 2002 Office Action imposing a restriction requirement in the above-referenced application, Applicants elect without traverse Group III, which corresponds to claim 18, directed to an antibody against human IL-11R, classified in Class 530, subclass 387.1.

Prior to examining the application, please amend the applications as follows.

In the claims:

Cancel claims 1-17 and 19-38.

18. (Amended) A composition comprising an antibody which specifically reacts with a human IL-11R protein.

Add the following new claims:

39. The composition of claim 18, wherein said antibody is a neutralizing antibody.